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Objectives. To evaluate the potential of iron-oxide dismutase excreted (SODeCRU) by T. cruzi as the antigen fraction in the
serodiagnosis of Chagas disease and compile new epidemiological data on the seroprevalence of this disease in the suburban
population of the city of Santiago de Quere´taro (Mexico). Design and Methods. 258 human sera were analyzed by the techniques
of ELISA and Western blot and using the homogenate and the SODeCRU. Results. A total of 31 sera were positive against
ELISA/SODeCRU (12.4%), while 30 sera proved positive by WB/SODeCRU (11.6%). The comparison between the technique
of ELISA and WB showed a sensitivity of 93%, and a specificity of 99%. The positive predictive value was 93% and the negative
predictive value was 99%, with a Kappa (κ) value of 1.Conclusions. These preliminary data reveal the degree of infection of nonrural
areas of Mexico and demonstrated that SODeCRU is an antigen useful to diagnose Chagas disease.
1. Introduction
Chagas disease, or American trypanosomiasis, is an infec-
tious tropical disease caused by the blood flagellate Try-
panosoma cruzi, which in its natural form is transmitted
by Hemipteran vectors colloquially called “vinchucas” in
Mexico and certain areas of South America. In addition,
other forms of infection are known: blood transfusions,
organ transplants, oral transmission, and congenital trans-
mission. The first phase of the infection (acute phase) has
clinical symptoms such as fever, discomfort, and cephalea
and thus can be confused with the flu. These symptoms remit
spontaneously, when the parasite passes to the mononu-
clear phagocytic system, nervous system (autonomic and
myoenteric plexus), and the myocardium. Thereafter, years
or even decades may pass without clinical manifestations
(indeterminate phase). This phase can be diagnosed only
by serological diagnosis. When the chronic phase appears
(anatomical alterations, megaesophagus, megacolon, and
especially myocardiopathy), the disease has no cure andmost
patients die a sudden death without the causes being known
[1].
The Pan American Health Organization estimates that
there are currently 7.7 million people infected by T. cruzi
in 21 endemic countries, with the appearance of 41,200
cases per year, and 14,400 children are born annually with
congenital Chagas disease. The countries most aﬀected are
Bolivia (6.8% of the cases reported), Argentina (4.1%),
El Salvador (3.4%), Honduras (3.1%), Paraguay (2.5%),
Guatemala (2%), Ecuador (1.7%), French Guyana, Guyana,
and Surinam (1.2%), Venezuela (1.2%), Nicaragua (1.1%),
Brazil (1%), and Mexico (1.3%) [2].
The enormous progress made in the control of Chagas
disease in the last few decades indicates clearly that the
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obstacles against the complete elimination of transmission
of T. cruzi to the human are mainly economic and political.
In this context, there are additional noteworthy advances
such as the more detailed understanding of the pathogen of
Chagas disease, genetic analyses, new diagnostic techniques,
and advances in the development of vaccines [3].
The diagnosis of Chagas disease depends on the phase
of the disease. In the acute phase, the diagnosis is made by
direct examination of the parasite in body fluids. In this acute
or reactivation [4] phase, when the parasitaemia is high, the
live parasite can be easily detected with its rapid movements.
Other techniques used for the direct observation of the
parasite include blood or droplet smear and exodiagnosis.
These methods present, respectively, a sensitivity of 60–70%
[5]. Despite being the most commonly used for their low
costs, these techniques do not present high sensitivity and
thus new inexpensive, quick methods are being sought [6, 7].
In the detection of Chagas disease, the PCR technique can
be used, although in addition to the high cost and not being
available in most of the laboratories of the endemic areas, it
has highly variable sensitivity (45%–96.5%) and can amplify
nonspecific products, giving false positives [5, 8, 9].
For all these reasons, the serological tests could represent
the eﬀective diagnosis for their sensitivity and relatively low
cost. These are divided into two groups: conventional tests,
which use the total parasite extract as the antigen, or soluble
extract of an antigen complex; nonconventional tests, which
usually use recombinant antigens or synthetic peptides [10].
Serological diagnosis gives diﬀerent results according to the
type of antigen used, the phase of the disease, and the type of
immunoglobulins (IgG or IgM). The choice of the antigen is
important for good results [11].
Many studies made to define a specific T. cruzi antigen
that would increase the specificity of the serodiagnosis. One
possibility is the iron-superoxide dismutase excreted by T.
cruzi (Fe-SODeCRU or SODeCRU), which, in previous stud-
ies, has proven strongly immunogenic and highly specific,
becoming useful to diagnose this disease [12, 13].
A prime objective of this study is to evaluate the potential
of Fe-SODe of T. cruzi as the antigen fraction, in the diagno-
sis of Chagas disease, through the analysis of 258 human sera
from the suburban area of the city of Santiago de Quere´taro
(Mexico), by the ELISA and Western Blot techniques. The
standardization of the ELISA and Western blot techniques
for screening Chagas patients, using the homogenate fraction
and the SODeCRU as the antigen fraction, enables us to work
towards the second objective: to compile epidemiological
data on the seroprevalence of Chagas disease in suburban
communities of the city of Santiago de Quere´taro, which
until now has not been studied.
2. Material andMethods
2.1. Parasites and Culture. Epimastigotes of T. cruzi
(MHOM/ME/2006/H-4) were grown in axenic medium
Trypanosomes Liquid Medium (MTL, Gibco) supplemented
with 10% heat-inactivated foetal bovine serum at 28◦C in
Falcon flasks [14].
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Figure 1: Seroprevalence of Chagas disease in suburban population
of Quere´taro city (Mexico) by ELISA (Homogenate and SODe) and
Western Blot SODe tests.
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Figure 2: Results of the assay of 258 serum samples from human,
collected in the suburban population of Quere´taro city (Mexico)
by enzyme-linked immunosorbent assay using the Fe-SODe by T.
cruzi, as antigen at a dilution of 1/100. The mean and standard
deviation of the optical densities of the control sera were used to
calculate the cut-oﬀ value (mean × 3 standard deviation).
2.2. Donor Selection and Study Design. The sample was taken
in the suburban areas (communities) of the city of Santiago
Quere´tao (in the state of Quere´taro, Mexico). The city is
located at an average altitude of 1,820m a.s.l., at 20◦ 35′
34.8′′ of latitude north and 100◦ 23′ 31.6′′ of longitude west,
a 221 km to the north-northwest of Mexico City. According
to a June 2010 census (XIII Censo de Poblacio´n y Vivienda),
the population of the city centre was 626,517, with 801,833
inhabitants in the greater city, and 1,096,978 in the entire
metropolitan zone, making it the 10th largest city in Mexico.
The average annual temperature is 26.4◦C, the maximum
average temperature being around 37◦C, in May, and the
minimum temperature is 11.5◦C, in January. The mean
annual precipitation of the state is 638.3, with rains in
summer from June to October (National Weather Service,
http://smn.cna.gob.mx/).
A total of 258 human sera were evaluated (collected
from February to October 2010), which were not grouped
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Figure 3: Immunoblot of the positive sera of the 258 human sera
collected in the suburban population of Quere´taro city (Mexico)
against the SODe antigen from T. cruzi epimastigotes at a serum
dilution of 1/100. Line C: SODe activity in isoelectrofocus and
staining following the technique of Beyer and Fridovich [15].
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Figure 4: Seroprevalence of Chagas disease distributed by genders
compared with the total of sera. Total samples analysed 258 (88
males and 170 females).
under any classification category (only numbered from 1
to 258). The sera were considered only as belonging to
suburban communities pertaining to the city of Santiago
de Quere´taro, where the dwellings built under conditions
of poverty occupy areas of hills and grazing areas, and
domestic animals were present. The following analytic data
were recorded: pathological alterations, age, sex, and place
of origin of the patients (Table 1). The donors signed an
informed consent form, and the study design was approved
by the Ethics Committee for Research of the University of
Granada (Spain).
A sample of 5mL of whole blood was drawn from the
ulnar vein of each human into assay tubes (Vacuttainer,
Beckton-Dickinson, USA) and kept at 4◦C. The negative
control sera (20, healthy or asymptomatic human, who had
never received a blood transfusion, nor organ transplant,
nor had lived in a country endemic of Chagas disease) were
obtained by the health services in Granada (Spain), which
were not reactive to the Western Blot techniques.
2.3. Total Extract of the Parasite (Fraction H). The parasite
culture (in the exponential growth phase) was concentrated
by centrifugation at 1500 rpm for 10min. The pellet of the
cells was washed twice and resuspended in ice-cold STE
buﬀer (0.25M sucrose, 25mM Tris-HCl, 1mM EDTA, pH
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Figure 5: Seroprevalence of Chagas disease distributed by age
groups compared with the total of sera. For range from 24 to 35,
n = 64, range from 36 to 50, n = 126, and range from 51 to 81,
n = 68.
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Figure 6: Associated pathologies in positive patients of Chagas
Disease. CCF: chronic cardiac failure; RF: renal failure; HT:
hyperthyroidism; DSP: dyslipidemia; MD-I: mellitus diabetes type
1; MD-II: mellitus diabetes type 2; 2 or more represents the
combination of two or more of these pathologies.
7.8) (Buﬀer 1). Afterwards, the pellet was suspended (0.5–
0.6 g wet weight mL−1) in 3mL of buﬀer 1 and disrupted
by three cycles of sonic disintegration, 30 s each at 60V.
The sonicated homogenate was centrifuged at 1500 rpm
for 10min at 4◦C, and the pellet was washed three times
with buﬀer 1 for a total supernatant fraction of 9mL. This
fraction was centrifuged (2500 rpm for 10min at 4◦C), and
the supernatant (fraction H) was collected [12].
2.4. Extraction and Purification of the SOD Excreted (SODe-
CRU). Parasite forms in the exponential growth phase,
obtained as described above, were concentrated by centrifu-
gation at 1500 rpm for 10min, the pellet of the cells was
washed twice in MTL medium without serum, and the
number of cells was counted in a haemocytometric chamber
and distributed into aliquots of 5 × 109 parasites/mL.
Afterwards, the parasites were again grown in MTL medium
without serum for 24 h; the supernatant was collected by
centrifugation at 1500 rpm for 10min and then passed
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Table 1: Relationship of positive sera of human from Queretaro (Mexico) by ELISA and Western Blot against diﬀerent antigen fractions of
Trypanosoma cruzi associated with age, gender, and pathology.
Sera
ELISA
HOG(a)
ELISA
SODe(b)
WB
SODe(c)
Age Gender Pathology(d)
8 − + + 53 M DM-I
10 − + + 40 F HPG
26 − + + 53 F DM-I + ICC
30 − + + 43 M CCF
40 − + + 32 F HPC
49 + + − 43 M ICC + DSP
50 + + + 39 F CCF
119 + + + 45 F HPG
122 + + + 35 M DM-II
133 − − + 80 M DM-II
141 − + + 27 F RF
157 − + − 37 F DSP
173 − + − 67 M DSP
185 + + + 33 F DSP
200 − + + 50 F DSP
203 + + + 48 M HPC
204 + − − 54 F DM-I + DSP
205 − + + 43 F CCF
206 − + + 27 F DSP
207 − + + 29 F CCF
212 − + + 48 M HT
214 − + + 35 M DSP
215 − + + 27 M DSP
218 − + + 39 M DM-I
221 − + + 40 F HPC
226 − − + 37 M CCF
229 − + + 51 F CCF
232 − + + 42 F DM-I
236 − + + 44 M HPG
238 − + + 49 M CCF
240 + + + 43 M CCF
245 − + + 43 F CCF
246 − + + 44 F CCF
247 − + + 43 F RF
(a)
ELISA-HOG: Enzyme-Linked Immunosorbent Assay (ELISA) using total parasite extract (HOG) of T. cruzi as antigen fraction.
(b)ELISA-SODe: Enzyme-Linked Immunosorbent Assay (ELISA) using excreted superoxide dismutase (SODe) by epimastigotes of T. cruzi as antigen fraction.
(c)WB-SODe: Western Blot (WB) using excreted superoxide dismutase (SODe) by epimastigotes of T. cruzi as antigen fraction.
(d)Pathology abreviations: MD-I: mellitus diabetes type 1; MD-II: mellitus diabetes type 2; HPG: hipertrigliceridemia; CCF: chronic cardiac failure; HPC:
hypercholesterolemia; DSP: dyslipidemia; RF: renal failure; HT: hyperthyroidism.
through a filter of 0.45-μm pore size, and solid ammonium
sulphate added. The protein fraction, which precipitated at
between 35 and 85% salt concentration, was centrifuged
(9000 rpm for 20min at 4◦C), redissolved in 2.5mL of
20mM potassium phosphate buﬀer (pH 7.8) containing
1mM EDTA (Buﬀer 2), and dialysed in a Sephadex G-
25 column (Pharmacia, PD 10), previously balanced with
Buﬀer 2, bringing it to a final volume of 2.5mL (fraction
SODeCRU) [16].
Both fractions, H and SODeCRU, were used as antigen
fractions in the ELISA and Western Blot assays. The protein
content was determined using the Bio-Rad test, based on the
Bradford method (Sigma Immunochemical, St. Louis), with
bovine serum albumin as a standard [16].
2.5. Serological Assay (ELISA). For the ELISA assay, H
and SODeCRU of the parasites, cultured and processed as
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Table 2: Evaluation of the reliability to detect Trypanosoma cruzi
antibodies, using ELISA technique with SODeCRU antigen, in 258
human sera from the suburban population in the city of Santiago de
Quere´taro (Mexico). The values given are estimated with Western
Blot as the comparator.
ELISA-SODeCRU
Sensitivity 93%
Specificity 99%
Positive predictive value 93%
Negative predictive value 99%
Kappa index 1
described above, were used as the antigen fraction in all cases.
The total homogenate (fraction H) and purified protein
fraction (SODeCRU) at a concentration of 5 and 1.5 μg,
respectively, was coated onto polystyrene microtitre plates
(Nunc, Denmark) in carbonate buﬀer (pH 8.2) for 2 h at
37◦C. The antigen remaining on the plate was eliminated
by washing three times with PBS-Tween 20 0.05% (washing
buﬀer). Free adsorption sites were taken by incubation (2 h at
37◦C) with blocking buﬀer (PBS-Tween 20 0.2%, BSA 1%).
After being washed as described previously, the plates were
incubated (45min at 37◦C) with serum dilution of 1 : 100
in washing buﬀer. After a second washing, the plates were
incubated in darkness for 20min with 100 μL of an enzyme-
conjugated antibody (Anti-IgG human peroxidase, Sigma) at
a dilution of 1 : 1000. The enzyme reaction was developed
with the chromogenic substrate OPD (o-Phenylenediamine
dihydrochloride, Sigma) and 10 μL of 30% H2O2 per 25mL
for 20min in the dark. The reaction was stopped by addition
of 50 μL of HCl 3N. Absorbance was read at 492 nm in a
microplate reader (Sunrise, TECAN). All the samples were
analysed in triplicate in polystyrene microtitre plates. Mean
and standard deviations (SD) of the optical densities of the
negative control sera (20 healthy humans) were used to
calculate the cut-oﬀ value (mean + 3 × SD) [12].
2.6. Western Blot Analysis. The antigen fraction of SODe-
CRU (at a concentration 1.5 μg of protein) was run on IEF 3–
9 gels and afterwards transferred to nitrocellulose membrane
(Hybond C Extra, Amersham Pharmacia Biotech ) using the
Phast-Transfer kit, as described by the manufacturer (Phast-
System handbook). The membrane was blocked for 2 h at
room temperature using 0.4% gelatine and 0.2% Tween 20
in PBS, followed by three washes in 0.1% Tween 20 in PBS
(PBS-T), and incubated for 2 h at room temperature, with
donor sera at a dilution of 1/100. Before being washed, the
membrane was further incubated for 2 h at room tempera-
ture with the second antibody, anti-human immunoglobulin
G (Fc specific) peroxidase conjugate (Sigma Immunochem-
ical; dilution 1/1,000). After washing as above, the substrate
diaminobenzidine (0.5mg/mL in buﬀer Tris/HCl 0.1M, pH
7.4, containing 1/5000 H2O2 [10 v/v]) was added and the
reaction stopped with several washes in distilled water [12].
3. Results and Discussion
Due to the high incidence of Chagas disease in a vast
variety of endemic areas and given the risk involved for
humans as well as other species of mammals that act as
natural reservoirs of T. cruzi, it is of utmost importance that
the populations at high risk be provided with prevention
measures. Everyday it becomes more necessary to develop a
highly sensitive and specific diagnostic method to oﬀer the
adequate treatment in the least time possible to reduce the
transmission of this parasitosis.
In this sense, the present study proposes the use of
SODeCRU as a highly eﬀective antigen to diagnose the
infections by T. cruzi in human populations living in
endemic zones of the disease. The diﬀerent homogenate
fractions (H) and SODeCRU of T. cruzi obtained through
the methodology described in Materials and Methods were
tested by ELISA, against 258 human sera from suburban
zones of the city of Santiago de Quere´taro (Mexico). Of the
total analysed, 8 sera proved positive against the H antigen
fraction of T. cruzi (ELISA/(H)), for a prevalence of 3.0%
(Figure 1).
For an evaluation of the antigenic potential of SODeCRU
and its possible use in the immunodiagnosis of Chagas
disease, these same sera were tested by the techniques
of ELISA/SODeCRU and WB/SODeCRU. In this case, 31
proved positive against ELISA/SODeCRU from T. cruzi (for
a prevalence of 12.0%), while 30 sera were positive for
WB/SODeCRU (prevalence of 11.6%) (Figure 1).
The agreement between the results for ELISA/SODeCRU
and WB/SODeCRU was almost 100%, with only the sera
49 and 157 showing positive with ELISA/SODeCRU but
negative for WB/Fe-SODe, and, conversely, serum 226
gave a positive with WB/SODeCRU but negative with
ELISA/SODeCRU (Figures 2 and 3). This minor discrepancy
indicated that the ELISA/SODeCRU can give false positives,
whereas the WB detects lower antigen concentrations.
However, the ELISA/SODeCRU continued to present high
sensitivity and specificity. In addition, due to the low cost
with respect to the WB, it can be considered a more adequate
tool to use in rural endemic areas, where an adequate health
system is not available to provide the equipment necessary to
run the high-cost diagnostic tests [16].
Also, the presence of false positives in the ELISA tech-
nique may be due to cross reactions with other protozoa,
fundamentally with Trypanosoma rangeli and with species
belonging to the species belonging to the genus Leishmania,
among others. This is a serious drawback in patients
from geographical areas harbouring other infectious agents.
However, in previous works, we have demonstrated that Fe-
SODe is species specific and thus does not present cross
reactions with other trypanosomatids [12, 14, 17].
The main challenge that health workers face when un-
dertaking an epidemiological study of Chagas disease is the
choice of the diagnostic method. Numerous authors support
the choice of serological tests [11, 18, 19], while others
suggest that serological methods are adequate only when
combined with additional ones, this implying the use of two
diﬀerent techniques to be compared [20].
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All parasitic protozoa investigated to data have been
found to possess superoxide dismutase (SOD) linked to
iron (Fe), this enzyme being considered a virulence factor,
permitting the invading parasites to survive the oxidant
oﬀensive activated by the host [21]. In addition, studies made
with parasites belonging to the family Trypanosomatidae
have corroborated the presence of this Fe-SODe [17, 22].
The diﬀerences between the protozoan Fe-SODe and those
of the hosts, together with the immunogenic properties,
make this Fe-SODe useful as a feasible molecular marker for
the development of new diagnostic methods, in addition to
potential therapeutic targets for designing new anti-Chagas
drugs with the potential of taking advantage of the structural
diﬀerences between Fe-SOD protozoans and the copper-
zinc-SOD of most eukaryotes [22].
Evaluating the results and taking into account the total
of the human sera analysed with the ELISA/SODeCRU tech-
nique and comparing it to the technique of WB/SODeCRU
as golden standard test, we found that the sensitivity of this
technique reached 93%, with specificity of 99% (Table 2).
The predictive value for positives with the ELISA/SODeCRU
technique was 93%, and the predictive value for negatives
was 99%. The Kappa (k) index of 1 confirmed that the
proportion of agreement was total beyond random, between
both assays ELISA/SODeCRU and WB/SODeCRU.
In general, because of the few cases documented para-
sitologically, Chagas disease is thought to be uncommon in
Mexico, although it is probable that, like other diseases, cases
are underrecorded for the lack of adequate diagnosis. The
cases reported in the country correspond to the states of de
Oaxaca, Chiapas, Jalisco, Michoaca´n, Guerrero, Zacatecas,
Yucata´n, Veracruz, Federal District of Me´xico, Sonora, and
San Luis Potosı´ [23, 24]. The prevalence reported is extremely
varied, the data going from 2.8% for the state of Nuevo Leo´n,
to 16.8% reported for the state of Veracruz [25, 26]. In the
state of Quere´taro, the prevalence of this disease is unknown
and data are available only for the year 2005 [17], when a
prevalence of 8.6% was found in the rural population. For
this reason, the second objective of the present study was to
provide new epidemiological data on the disease in this state
of Mexico, focusing on the suburban areas of the capital of
this state.
The prevalence found in the present study is significantly
greater than that reported in 2005. This could be due to a
transfer of the disease from the rural setting to the urban
one, and, on the other hand, it could be due to an increase in
the disease. Prevalence in males was higher than in females
(17.0% versus 11.2%, resp.) (Figure 4), in agreement with
findings reported by other authors [27], although, in some
cases [28], the diﬀerences are not so significant. These dis-
crepancies might be the result of cultural, behavioural, and
socioeconomic diﬀerences among regions. The prevalence
by ages shows that the group of persons between 36 and
50 years presented the highest prevalence (15.9%; Figure 5).
The individuals that tested positive in our study presented
analytical alterations, some of them compatible with the
chronic phase of the disease.
Some 35% of the patients presented some type of
dyslipidaemia (DSP), diabetes mellitus types I and II, acute
kidney failure followed by chronic heart failure, the latter
reaching 29% of the interviewees, who presented high values
of cardiac enzymes (CK-MB; Figure 6).
It was demonstrated that Fe-SOD excreted by T. cruzi
was highly immunogenic and of high specificity, making it
useful to diagnose Chagas disease at the same time as it
provided epidemiological data on the seroprevalence of this
disease in the suburban population of Santiago de Quere´taro,
formerly unstudied. These preliminary data reveal the degree
of infection of nonrural areas of Mexico.
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